Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
about
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patientsHER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsGold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situHER-2/neu as a predictive marker of response to breast cancer therapy.HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancerRole of HER2 gene overexpression in breast carcinoma.Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumorsCorrelation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection.The epidermal growth factor receptor family in breast cancer.Testing for HER2 in Breast Cancer: A Continuing Evolution.Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registryTrastuzumab-associated cardiotoxicity.Prognostic and predictive value of HER2/neu oncogene in breast cancer.Rhein induces apoptosis in human breast cancer cells.Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection.Targeted therapy in breast cancer: the HER-2/neu gene and protein.Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future TherapySoluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancerStromal cell cathepsin D expression and long-term survival in breast cancer.Prognostic factors and recurrence in breast cancer: experience at the national cancer institute of MexicoNeoplastic progression of breast epithelial cells--a molecular analysis.Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinomaTargeted therapies in gastric cancer and future perspectives.HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.The progress of targeted therapy in advanced gastric cancerPrecision medicine and personalized breast cancer: combination pertuzumab therapy.Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study.Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients.Is there a dose-dependent effect of genetic susceptibility loci for gastric cancer on prognosis of the patients?Transfection of the c-erbB2/neu gene upregulates the expression of sialyl Lewis X, alpha1,3-fucosyltransferase VII, and metastatic potential in a human hepatocarcinoma cell line.Biological indices in the assessment of breast cancer.HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.Determination of the Proteomic Response to Lapatinib Treatment using a comprehensive and reproducible ion-current-based proteomics strategy.Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways.Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study.
P2860
Q21261244-C7064AF8-EB6A-4CAE-BE2B-A4EF1472EDC7Q25257668-811F093E-7225-444A-BA0B-0ADC6E88B094Q30444859-B51EEBD8-1E47-4905-8EE7-003AD0B1A12BQ30828754-80426A78-F9DE-4114-BB35-3892FF8F7CCBQ33317621-4C5429D9-6A2C-4842-80F5-DE94D31AE575Q33538428-86DEE8BF-7076-4FE9-867E-AE00A4D9161BQ33686182-F709D56E-36F4-4D23-88EE-E8E8CCC37BE2Q33810080-1F78695D-7DCA-41EB-BA7D-8076317BFFDEQ34047882-A8F7F19B-B38B-4C28-950A-59E0128D792AQ34353223-EE7A5517-5358-45B2-811C-5D04D3FBF5E6Q34363400-6FBAB833-FAE4-4E61-B83F-495FD5D30A17Q34424285-27334AA8-6498-4969-82DC-31D92A857C72Q34503715-93FC2180-B3D2-42D2-BB86-50177FED41E1Q34867708-687183B9-BAAC-413B-8B45-158EBBAB3C33Q34954864-3E46E3E0-D1C8-4525-9B58-2D133C37E550Q35294642-F646506C-56D5-43D5-9D2E-A38F6FBEBA75Q35594687-56802B70-C5C8-4F2A-8CF0-C7CB25A96940Q35648508-9FB44D5B-896C-4747-BEF6-47CEB57E50DBQ35654022-40DBDB3A-1425-4BB0-8B06-D6B4EE6CD7D4Q36079736-31606ADF-E4DB-452D-9658-C21DB7C2DE31Q36079902-0306B949-70D2-4042-AE89-CE7DB27226A5Q36102243-606D6F27-3BE0-4AD5-872C-5EB22F6D0752Q36114717-ACB9FEBC-E4C3-4C20-960F-05BCFA6833B1Q36134697-67A453C6-38B8-46BF-92E4-69A38D2934C1Q36431350-56C41FB8-DE39-4B46-8490-64A916D96907Q36471685-E205F5CF-EC79-4F0B-8E69-E6F5DCF4BB03Q37277175-C7668BD1-6F73-4542-8F47-B1FDB08378BDQ37326072-81A62826-2234-4DF7-AF7A-B4437E2B55A3Q37427269-451E9CA2-6E00-4877-AD07-BDCF2B4F41FCQ37687975-8740F84A-AA48-44AF-8D89-B924B81C1228Q38458593-10EEF3D9-37A4-430D-97C1-871F347B0602Q38484552-1E52E9FB-BCBD-47A8-A3F7-8E31C19C1B0FQ38645153-C546F85A-2C0A-4F5A-8954-62DA418508A1Q39207324-9B629477-A3F5-4F46-B7E5-4988B054C0F9Q40796882-2567DEC9-3849-4F05-B600-40BC2F2ABFB7Q40848953-0782772E-FE3E-4AB7-9DD2-BF4094317131Q41757403-4F946B23-37E7-4D84-98BE-BF992BE69DFAQ42378682-A32BEE2C-33BD-41D3-B193-56CB4F488F19Q43124366-3A47818F-8EA0-4A2C-8FAC-9212C451C2ECQ43754966-6EADE941-5806-4375-834A-8D8C5C651ADC
P2860
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Prognostic significance of HER ...... t cancer: a 30-year follow-up.
@en
Prognostic significance of HER ...... t cancer: a 30-year follow-up.
@nl
type
label
Prognostic significance of HER ...... t cancer: a 30-year follow-up.
@en
Prognostic significance of HER ...... t cancer: a 30-year follow-up.
@nl
prefLabel
Prognostic significance of HER ...... t cancer: a 30-year follow-up.
@en
Prognostic significance of HER ...... t cancer: a 30-year follow-up.
@nl
P2093
P1476
Prognostic significance of HER ...... t cancer: a 30-year follow-up.
@en
P2093
P304
P356
10.1200/JCO.1992.10.7.1044
P407
P577
1992-07-01T00:00:00Z